- Patients with oligometastatic NSCLC who received pembrolizumab after locally ablative therapy (LAT) had progression-free survival (PFS) nearly 3 times longer than PFS reported in previous studies of LAT alone.
Why this matters
- This study is the first to show improved outcomes with immunotherapy after LAT in oligometastatic NSCLC.
- A randomized, multicenter trial of LAT with/without pembrolizumab is planned.
- Phase 2 trial.
- 45 patients with oligometastatic NSCLC at diagnosis received pembrolizumab 4-12 weeks after undergoing LAT (surgery, chemoradiotherapy, stereotactic radiotherapy, and/or interventional ablation).
- 25.0-month median follow-up.
- Funding: Merck & Co., Inc., Kenilworth, NJ, USA; the Abramson Cancer Center.
- Median PFS from the start of LAT (PFS-L) was significantly longer than that in previously reported studies (19.1 vs 6.6 months; P=.005).
- Median PFS from the start of pembrolizumab therapy (PFS-P) was 18.7 months.
- Mean OS was 90.9% at 1 year and 77.5% at 2 years.
- 23 patients had disease progression.
- Only 1 patient reported a grade 4 adverse event (pneumonitis).
- No association between PFS-L and PD-L1 or CD8 status.
- No decrease in QoL was reported.
- Single-center, single-group study.